Bone mineral density (BMD) improved in the 96 weeks after patients switched from a combination containing tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) as part of the single-tablet regimen elvitegravir/cobicistat/emtricitabine/TA...
The burden that HIV places on women, particularly adolescent girls and young women from low- and middle-income countries, is compounded by the global burden of human papillomavirus (HPV) infection and cervical cancer.
A report from the PROMISE study showed no adverse bone mineral effect, linked to maternal tenofovir disoproxil fumarate (TDF), in exposed infants.
Researchers investigated using the combined ledipasvir/sofosbuvir for only six weeks in a small group of HIV-positive people diagnosed with acute hepatitis C.
While neurocognitive problems may appear very early on in acute HIV infection, "there is a profound misconception that HIV will affect the brain in everyone," says Bruce J. Brew, M.D., F.R.A.C.P.
Further research bolsters findings that HIV-positive people are at increased risk for developing osteopenia and osteoporosis and, in rare cases, osteonecrosis.
A small clinical trial found that a single infusion of zoledronic acid prevented ART-induced bone loss for one year.
Recent research comes from a switch study for tenofovir alafenamide (TAF), a new version of tenofovir, which showed a 2% improvement in bone density for those taking the new form of the drug.
Liz Highleyman, editor-in-chief of HIVandHepatitis.com, spoke with Jürgen Rockstroh, M.D., Kenneth Sherman, M.D., Ph.D., and Dost Sarpel, M.D., about the latest research on the treatment of hepatitis B and C.
Three studies offer reassuring news that adverse kidney changes that accompany Truvada use for PrEP are rarely serious and universally reverse after stopping the medication, but also that older people and those with the best adherence might need to b...